Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome

American Journal of Medicine

Volumn 116, Issue 8, 2004, Pages 546-554

  Davidson, Michael B ^a   Thakkar, Snehal ^a   Hix, John K ^a   Bhandarkar, Naveen D ^b   Wong, Alan ^a   Schreiber, Martin J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BICARBONATE; CALCIUM PHOSPHATE; CATION EXCHANGE RESIN; CONTRAST MEDIUM; GLUCONATE CALCIUM; INSULIN; PHOSPHATE; POTASSIUM; RASBURICASE; URATE OXIDASE; URIC ACID; URICOZYME; XANTHINE OXIDASE INHIBITOR;

ACUTE KIDNEY FAILURE; ACUTE LYMPHOCYTIC LEUKEMIA; ALKALINIZATION; ALLERGIC REACTION; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIALYSIS; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; HEART VENTRICLE ARRHYTHMIA; HEMOFILTRATION; HUMAN; HYDRATION; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOCALCEMIA; KIDNEY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MUSCLE CRAMP; MUSCLE WEAKNESS; PARESTHESIA; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PODAGRA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL; URINARY EXCRETION;

ANTINEOPLASTIC AGENTS; ELECTROLYTES; GOUT SUPPRESSANTS; HUMANS; KIDNEY FAILURE, ACUTE; RENAL DIALYSIS; TUMOR LYSIS SYNDROME;

EID: 1842425574     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.09.045     Document Type: Review

References (84)

1. Crittenden D.R., Ackerman G.L. Hyperuricemic acute renal failure in disseminated carcinoma. Arch Intern Med. 137:1977;97-99.
2. Jasek A.M., Day H.J. Acute spontaneous tumor lysis syndrome. Am J Hematol. 47:1994;129-131.
3. Alkhuja S., Ulrich H. Acute renal failure from spontaneous acute tumor lysis syndrome a case report and review. Ren Fail. 24:2002;227-232.
4. Feld J., Mehta H., Burkes R.L. Acute spontaneous tumor lysis syndrome in adenocarcinoma of the lung a case report. Am J Clin Oncol. 23:2000;491-493.
5. Agha-Razii M., Amyot S.L., Pichette V., et al. Continuous veno-venous hemodiafiltration for the treatment of spontaneous tumor lysis syndrome complicated by acute renal failure and severe hyperuricemia. Clin Nephrol. 54:2000;59-63.
6. Bedrna J., Polcák J. Akuter Harnleiterverschluss nach Bestrahlung chronischer Leukämien mit Röntgenstrahlen. Med Klin. 25:1929;1700-1701.
7. Cohen L.F., Balow J.E., Magrath I.T., et al. Acute tumor lysis syndrome a review of 37 patients with Burkitt's lymphoma. Am J Med. 68:1980;486-491.
8. Altman A. Acute tumor lysis syndrome. Semin Oncol. 28:(suppl 5):2001;3-8.
9. Jeha S. Tumor lysis syndrome. Semin Hematol. 38:(suppl 10):2001;4-8.
10. Flombaum C.D. Metabolic emergencies in the cancer patient. Semin Oncol. 27:2000;322-334.
11. Sewani H.H., Rabatin J.T. Acute tumor lysis syndrome in a patient with mixed small cell and non-small cell tumor. Mayo Clinic Proc. 77:2002;722-728.
12. Kalemkerian G.P., Darwish B., Varteraisan M.L. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med. 103:1997;363-367.
13. Persons D.A., Garst J., Vollmer R., et al. Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin. Am J Clin Oncol. 21:1998;426-429.
14. Zigrossi P., Brustia M., Bobbio F., et al. Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report. Ann Ital Med Int. 16:2001;112-117.
15. Rostom A.Y., El-Hussainy G., Kandil A., Allam A. Tumor lysis syndrome following hemi-body irradiation for metastatic breast cancer. Ann Oncol. 11:2000;1349-1351.
16. Sklarin N.T., Markham M. Spontaneous recurrent tumor lysis syndrome in breast cancer. Am J Clin Oncol. 18:1995;71-73.
17. Stark M.E., Dyer M.C., Coonley C.J. Related fatal acute tumor lysis syndrome with metastatic breast carcinoma. Cancer. 60:1987;762-764.
18. Cech P., Block J.B., Cone L.A., et al. Tumor lysis syndrome after tamoxifen flare. N Engl J Med. 315:1986;263-264.
19. Drakos P., Bar-Ziv J., Catane R. Tumor lysis syndrome in nonhematologic malignancies. Am J Clin Oncol. 17:1994;502-505.
20. Hain R.D., Rayner L., Weitzman S., et al. Acute tumour lysis syndrome complicating treatment of stage IVS neuroblastoma in infants under six months old. Med Pediatr Oncol. 23:1994;136-139.
21. Tomlinson G.C., Solberg L.A. Jr. Acute tumor lysis syndrome with metastatic medulloblastoma. A case report. Cancer. 53:1984;1783-1785.
22. Yokoi K., Miyazawa N., Kano Y., et al. Tumor lysis syndrome in invasive thymoma with peripheral blood T-cell lymphocytosis. Am J Clin Oncol. 20:1997;86-89.
23. Khan J., Broadbent V.A. Tumor lysis syndrome complicating treatment of widespread metastatic abdominal rhabdomyosarcoma. Pediatr Hematol Oncol. 10:1993;151-155.
24. Khalil A., Chammas M., Shamseddine A., et al. Fatal acute tumor lysis syndrome following treatment of vulvar carcinoma case report. Eur J Gynaecol Oncol. 19:1998;415-416.
25. Shamseddine A.I., Khalil A.M., Wehbeh M.H. Acute tumor lysis syndrome with squamous cell carcinoma of the vulva. Gynecol Oncol. 51:1993;258-260.
26. Dirix L.Y., Prove A., Becquart D., et al. Tumor lysis syndrome in a patient with metastatic Merkel cell carcinoma. Cancer. 67:1991;2207-2210.
27. Pentheroudakis G., O'Neill V.J., Vasey P., et al. Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Report of two cases. Support Care Cancer. 9:2001;554-557.
28. Barton J.C. Tumor lysis syndrome in nonhematopoietic malignancies. Cancer. 64:1989;738-740.
29. Bilgrami S.F., Fallon B.G. Tumor lysis syndrome after combination chemotherapy for ovarian cancer. Med Pediatr Oncol. 21:1993;521-524.
30. Habib G.S., Saliba W.R. Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma a case report and review of the literature. Am J Med Sci. 323:2002;155-157.
31. Stoves J., Richardson D., Patel H. Tumour lysis syndrome in a patient with metastatic melanoma treated with biochemotherapy. Nephrol Dial Transplant. 16:2001;188-189.
32. Razis E., Arlin Z., Ahmed T., et al. Incidence and treatment of tumour lysis syndrome in patients with acute leukaemia. Acta Haematol. 91:1994;171-174.
33. Montalban C., Liano F., Aguilera A. Tumour lysis syndrome after treatment of chronic lymphocytic leukaemia with fludarabine. Postgrad Med J. 70:1994;651-652.
34. Castro M.P., Van Auken J., Spencer-Cisak P., et al. Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma. Cancer. 85:1999;1055-1059.
35. Dillman R.O. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 18:1999;465-471.
36. Fleming D.R., Henslee-Downey P.J., Coffey C.W. Radiation induced acute tumor lysis syndrome in the bone marrow transplant setting. Bone Marrow Transplant. 8:1991;235-236.
37. Fer M.F., Bottino G.C., Sherwin S.A., et al. Atypical tumor lysis syndrome in a patient with T-cell lymphoma treated with recombinant leukocyte interferon. Am J Med. 77:1984;953-956.
38. Coutinho A.K., de O Santos M., Pinczowski H., et al. Tumor lysis syndrome in a case of chronic lymphocytic leukemia induced by high-dose corticosteroids. Am J Hematol. 54:1997;85-86.
39. Malik I.A., Abubakar S., Alam F., et al. Dexamethasone-induced tumor lysis syndrome in high-grade non-Hodgkin's lymphoma. South Med J. 87:1994;409-411.
40. Sparano J., Ramirez M., Wiernik P.H. Increasing recognition of corticosteroid-induced tumor lysis syndrome in non-Hodgkin's lymphoma. Cancer. 65:1990;1072-1073.
41. Kelton J., Kelley W.N., Holmes E.W. A rapid method for the diagnosis of acute uric acid nephropathy. Arch Intern Med. 138:1978;612-615.
42. Lorigan P.C., Woodings P.L., Morgenstern G.R., et al. Tumour lysis syndrome, case report and review of the literature. Ann Oncol. 7:1996;631-636.
43. Sondheimer J.H., Migdal S.D. Toxic nephropathies. Crit Care Clin. 3:1987;883-907.
44. Jones D.P., Mahmoud H., Chesney R.W. Tumor lysis syndrome pathogenesis and management. Pediatr Nephrol. 9:1995;206-212.
45. Sallan S. Management of acute tumor lysis syndrome. Semin Oncol. 28:(suppl 5):2001;9-12.
46. Singer G.G., Brenner B.M. Fluid and electrolyte disturbances. Braunwald E., Fauci A.S., Kasper D.L., et al. Harrison's Principles of Internal Medicine. 15th ed. 2001;271-283 McGraw-Hill, New York, New York.
47. DeConti R.C., Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med. 274:1966;481-486.
48. Masera G., Jankovic M., Zurlo M.G., et al. Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr. 100:1982;152-155.
49. Chua C.C., Greenberg M.L., Viau A.T., Nucci M., Brenckman W.D. Jr, Hershfield M.S. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med. 109:1988;114-117.
50. Pui C.H., Relling M.V., Lascombes F., et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia. 11:1997;1813-1816.
51. Smalley R.V., Guaspari A., Haase-Statz S., et al. Allopurinol intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol. 18:2000;1758-1763.
52. Pui C., Mahmoud H.H., Wiley J.M., et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 19:2001;697-704.
53. Goldman S.C., Holcenberg J.S., Finklestein J.Z., et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 97:2001;2998-3003.
54. Wilcox W.R., Khalaf A., Weinberger A., et al. Solubility of uric acid and monosodium urate. Med Biol Eng. 10:1972;522-531.
55. Conger J.D., Falk S.A., Guggenheim S.J., Burke T.J. A micropuncture study of the early phase of acute urate nephropathy. J Clin Invest. 58:1976;681-689.
56. Arrambide K., Toto R.D. Tumor lysis syndrome. Semin Nephrol. 13:1993;273-280.
57. Monballyu J., Zachee P., Verberckmoes R., et al. Transient acute renal failure due to tumor-lysis-induced severe phosphate load in a patient with Burkitt's lymphoma. Clin Nephrol. 22:1984;47-50.
58. Conger J.D., Falk S.A. Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest. 59:1977;786-793.
59. Rundles R.W., Wyngaarden J.B., Hitching G.H., Elison G.B., Silberman H.R. Effects of xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia, and gout. Trans Assoc Am Phys. 76:1963;126-140.
60. Feusner J, Farber MS. Role of intravenous allopurinol in the management of acute tumor lysis syndrome. Semin Oncol 2001(suppl 5):13-18
61. Allopurinol [prescribing information]. Corona, California: Watson Laboratories; June 2002
62. Band P.R., Silverberg D.S., Henderson J.F., et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med. 283:1970;354-357.
63. Brogard J.M., Coumaros D., Franckhauser J., et al. Enzymatic uricolysis a study of the effect of a fungal urate-oxydase. Rev Eur Etud Clin Biol. 17:1972;890-895.
64. Yeldandi A.V., Yeldandi V., Kumar S., et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates nonsense mutations. Gene. 109:1991;281-284.
65. Patte C., Sakiroglu O., Sommelet D. European experience in the treatment of hyperuricemia. Semin Hematol. 38:(suppl 10):2001;9-12.
66. Rozenberg S., Koeger A.C., Bourgeois P. Urate-oxydase for gouty arthritis in cardiac transplant recipients. J Rheumatol. 20:1993;2171.
67. Leplatois P., Le Douarin B., Loison G. High-level production of a peroxisomal enzyme Aspergillus flavus uricase accumulates intracellularly and is active in Saccharomyces cerevisiae. Gene. 122:1992;139-145.
68. Bayol A., Capdevielle J., Malazzi P., et al. Modification of a reactive cysteine explains differences between rasburicase and Uricozyme, a natural Aspergillus flavus uricase. Biotechnol Appl Biochem. 36:(pt 1):2002;21-31.
69. Elitek (rasburicase) [prescribing information]. New York, New York: Sanofi-Synthelabo Inc.; July 2002
70. Pui C.H. Rasburicase a potent uricolytic agent. Exp Opin Pharmacother. 3:2002;433-452.
71. Brant J.M. Rasburicase an innovative new treatment for hyperuricemia associated with tumor lysis syndrome. Clin J Oncol Nurs. 6:2002;12-16.
72. Goldsmith R.S., Ingbar S.H. Inorganic phosphate treatment of hypercalcemia of diverse etiologies. N Engl J Med. 274:1966;1-7.
73. Kjellstrand C.M., Campbell D.C., von Hartitzsch B., et al. Hyperuricemic acute renal failure. Arch Intern Med. 133:1974;349-359.
74. Davies S.P., Kox W.J., Brown E.A. Clearance studies in patients with acute renal failure treated by continuous arteriovenous haemodialysis. Contrib Nephrol. 93:1991;117-119.
75. Jeffrey R.F., Khan A.A., Prabhu P., et al. A comparison of molecular clearance rates during continuous hemofiltration and hemodialysis with a novel volumetric continuous renal replacement system. Artif Organs. 18:1994;425-428.
76. Procaccini D.A., Querques M., Tappi A., Strippoli P. Peritoneal clearances. Long term study. ASAIO Trans. 34:1988;437-440.
77. Descombes E., Perriard F., Fellay G. Diffusion kinetics of urea, creatinine and uric acid in blood during hemodialysis. Clinical implications. Clin Nephrol. 40:1993;286-295.
78. Duke M. Peritoneal dialysis in leukemia and uric acid nephropathy. Am J Med Sci. 245:1963;426-431.
79. Pichette V., Leblanc M., Bonnardeaux A., et al. High dialysate flow rate continuous arteriovenous hemodialysis a new approach for the treatment of acute renal failure and tumor lysis syndrome. Am J Kidney Dis. 23:1994;591-596.
80. Schelling J.R., Ghandour F.Z., Strickland T.J., et al. Management of tumor lysis syndrome with standard continuous arteriovenous hemodialysis case report and a review of the literature. Ren Fail. 20:1998;635-644.
81. Heney D., Essex-Cater A., Brocklebank J.T., et al. Continuous arteriovenous haemofiltration in the treatment of tumour lysis syndrome. Pediatr Nephrol. 4:1990;245-247.
82. Sakarcan A., Quigley R. Hyperphosphatemia in tumor lysis syndrome the role of hemodialysis and continuous veno-venous hemofiltration. Pediatr Nephrol. 8:1994;351-353.
83. Jaing T.H., Hsueh C., Tain Y.L., et al. Tumor lysis syndrome in an infant with Langerhans cell histiocytosis successfully treated using continuous arteriovenous hemofiltration. J Pediatr Hematol Oncol. 23:2001;142-144.
84. Saccente S.L., Kohaut E.C., Berkow R.L. Prevention of tumor lysis syndrome using continuous veno-venous hemofiltration. Pediatr Nephrol. 9:1995;569-573.